| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421585A1 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | CA2420932A1 Novel mammalian nuclear receptor l66 and methods of use |
| 03/21/2002 | CA2419894A1 Process for high throughput screening of cpg-based immuno-agonist/antagonist |
| 03/21/2002 | CA2391407A1 Antigenic proteins of shrimp white spot syndrome virus and uses thereof |
| 03/20/2002 | EP1188835A1 A vector for the expression of two foreign genes |
| 03/20/2002 | EP1188828A1 Reg-binding protein |
| 03/20/2002 | EP1188448A2 Heparin-binding growth factors for gene therapy and anterior eye disorders |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187929A2 Novel liposomal vector complexes and their use in gene therapy |
| 03/20/2002 | EP1187926A1 Promoters from atlantic salmon |
| 03/20/2002 | EP1187923A1 Apoptosis inhibition by adenovirus e3/6.7k |
| 03/20/2002 | EP1187919A2 Recombinant adenoviruses for the sodium/iodide symporter (nis) |
| 03/20/2002 | EP1187917A1 Cd44 splice variant associated with rheumatoid arthritis |
| 03/20/2002 | EP1187916A2 Identification and molecular characterisation of proteins, expressed in the tick salivary glands |
| 03/20/2002 | EP1187915A2 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 03/20/2002 | EP1187913A1 Screening method for peptides |
| 03/20/2002 | EP1187911A2 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| 03/20/2002 | EP1187908A1 42 human secreted proteins |
| 03/20/2002 | EP1187852A1 EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
| 03/20/2002 | EP1187849A1 Meth1 and meth2 polynucleotides and polypeptides |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187842A1 Human tumor necrosis factor receptor tr10 |
| 03/20/2002 | EP1187806A2 Spermine:peptide-based surfactant compounds |
| 03/20/2002 | EP1187634A1 Cell growth inhibition |
| 03/20/2002 | EP1187627A2 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 03/20/2002 | EP1187620A1 Antisense modulation of b7 protein expression |
| 03/20/2002 | EP0986568B1 Novel class of nucleic acid cationic transfecting agents |
| 03/20/2002 | EP0591385B1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 03/20/2002 | CN1341121A Expression and export of anti-obesity proteins as Fc fusion proteins |
| 03/20/2002 | CN1341029A Use of an OmpA enterobacteriumprotein associated with the ELAGIGILTV peptide for treating melanomas |
| 03/19/2002 | US6359193 Nucleotide sequences of lats genes |
| 03/19/2002 | US6359127 Oligonucleotide for use in treatment of cancer and nervous system disorders |
| 03/19/2002 | US6359124 Nucleotide sequences for use in the diagnosis, detection and treatment of arrhythmia, long q-t syndrome and cancers |
| 03/19/2002 | US6359116 Compounds |
| 03/19/2002 | US6359054 For gene therapy |
| 03/19/2002 | US6358931 Oligonucletide conjugated to imidazole; intercalation and coordination compounds; medical diagnosis, gene therapy; antisense agents |
| 03/19/2002 | US6358741 Polynucleotide coding propagation regulator; for treating cell proliferative defects |
| 03/19/2002 | US6358732 Nucleotide sequences preferential polypeptides for use in the treatment of defects in central nervous system |
| 03/19/2002 | US6358727 Nucleotide sequences coding binding protein for use in treatment and prevention of infections |
| 03/19/2002 | US6358723 Deoxyribonuclease IIβ proteins and cDNAs |
| 03/19/2002 | US6358707 Polynucleotide sequences coding polypeptide associated with cellular secretion; for use in treatment of diabetes, stroke, atherosclerosis, restenosis, thrombosis, autoimmune disease, psoriasis, arthritis, crohn's, and inflammatory defects |
| 03/19/2002 | US6358702 Polynucleotides encoding human Hox C10 |
| 03/19/2002 | US6358693 AMPA-binding human gluR4 receptor methods |
| 03/19/2002 | US6358524 Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use |
| 03/19/2002 | US6358507 Transgene expression systems |
| 03/19/2002 | US6358443 Directing microdroplets into freezing section containing a liquefied gas; contacting frozen microdroplets in extraction section with liquid non-solvent to extract solvent into non-solvent to form microparticles |
| 03/19/2002 | US6357163 Use of nucleic acid analogues in diagnostics and analytical procedures |
| 03/15/2002 | CA2318517A1 Modulation of homologous recombination with single stranded dna binding proteins |
| 03/14/2002 | WO2002021140A1 Nucleic acid sequences and proteins involved in cellular senescence |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020814A1 Self-rearranging dna vectors |
| 03/14/2002 | WO2002020813A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | WO2002020810A1 High efficiency retroviral vector which contains genetically engineered cellular non-coding sequence harboring splicing acceptor |
| 03/14/2002 | WO2002020803A1 Human source gene leading sequence, gene vector and gene expression strategy |
| 03/14/2002 | WO2002020801A2 26199, 33530, 33949, 47148, 50226, and 58764, human transferase family members and uses therefor |
| 03/14/2002 | WO2002020786A2 Kinase d interacting protein |
| 03/14/2002 | WO2002020782A1 A sense andantisnse oligonucleotides of v-erbb gene and uses thereof |
| 03/14/2002 | WO2002020773A2 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| 03/14/2002 | WO2002020769A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | WO2002020762A2 Tnf receptor-like molecules and uses thereof |
| 03/14/2002 | WO2002020756A2 Secretory molecules |
| 03/14/2002 | WO2002020754A2 Molecules for diagnostics and therapeutics |
| 03/14/2002 | WO2002020747A2 Regulation of human tyrosine phosphatase-like enzyme |
| 03/14/2002 | WO2002020732A2 Regulation of human map kinase phosphatase-like enzyme |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020721A2 Vectors derived from south african arbovirus no. 86 |
| 03/14/2002 | WO2002020615A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | WO2002020565A2 Collections of repeat proteins comprising repeat modules |
| 03/14/2002 | WO2002020563A2 RECEPTOR IN THE EDb FIBRONECTIN DOMAIN |
| 03/14/2002 | WO2002020551A1 Antisense modulation of e2f transcription factor 2 expression |
| 03/14/2002 | WO2002020550A1 Antisense modulation of mekk3 expression |
| 03/14/2002 | WO2002020549A1 Antisense modulation of glioma-associated oncogene-1 expression |
| 03/14/2002 | WO2002020547A1 Antisense modulation of bh3 interacting domain death agonist expression |
| 03/14/2002 | WO2002020546A1 Antisense modulation of phosphorylase kinase alpha 1 expression |
| 03/14/2002 | WO2002020545A1 Antisense modulation of a20 expression |
| 03/14/2002 | WO2002020088A1 Method and system for myocardial infarction repair |
| 03/14/2002 | WO2002020060A1 Vp22 protein/nucleic acid aggregates, uses thereof |
| 03/14/2002 | WO2002020047A2 Chlamydial peptides and their mimics in demyelinating disease |
| 03/14/2002 | WO2002020038A2 Method for down-regulating ige |
| 03/14/2002 | WO2002020036A1 Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or a dna sequence of the koc promoter |
| 03/14/2002 | WO2002020032A1 Stat3 agonists and antagonists and therapeutic uses thereof |
| 03/14/2002 | WO2002019986A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 03/14/2002 | WO2002019966A2 Cardiac arrhythmia treatment methods |
| 03/14/2002 | WO2001090189A3 G-protein coupled receptor org3. |
| 03/14/2002 | WO2001085981A3 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
| 03/14/2002 | WO2001081581A3 Compositions and methods for the therapy and diagnosis of acne vulgaris |
| 03/14/2002 | WO2001080901A3 Gene directed enzyme prodrug therapy (gdept) for cell ablation |
| 03/14/2002 | WO2001079502A3 Vectors for gene therapy |
| 03/14/2002 | WO2001077358A3 Herpes viruses for immune modulation |
| 03/14/2002 | WO2001074861A3 Compositions and methods for tissue specific gene regulation therapy |
| 03/14/2002 | WO2001066749A3 A member of the lectin superfamily |
| 03/14/2002 | WO2001066149A3 Nucleic acid formulations for gene delivery and methods of use |
| 03/14/2002 | WO2001059129A3 Mammalian secreted group iii phospholipase a2 |
| 03/14/2002 | WO2001059064A3 Nucleic acids, proteins, and antibodies |
| 03/14/2002 | WO2001058921A9 Methods and compositions for generating angiostatin |
| 03/14/2002 | WO2001058918A3 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments |